• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640428)   Today's Articles (1841)   Subscriber (50384)
Download
Number Citation Analysis
26
Prueksaritanont T, Hochman JH, Meng Y, Pudvah NT, Barrish A, Ma B, Yamazaki M, Fernandez-Metzler C, Lin JH. Renal elimination of a novel and potent αvβ3integrin antagonist in animals. Xenobiotica 2008;34:1059-74. [PMID: 15801548 DOI: 10.1080/00498250400015277] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
27
Mills DA, Fekrazad HM, Verschraegen CF. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers. CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000) 2008;9:647-657. [PMID: 18516764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
28
Egbertson MS, Moritz HM, Melamed JY, Han W, Perlow DS, Kuo MS, Embrey M, Vacca JP, Zrada MM, Cortes AR, Wallace A, Leonard Y, Hazuda DJ, Miller MD, Felock PJ, Stillmock KA, Witmer MV, Schleif W, Gabryelski LJ, Moyer G, Ellis JD, Jin L, Xu W, Braun MP, Kassahun K, Tsou NN, Young SD. A potent and orally active HIV-1 integrase inhibitor. Bioorg Med Chem Lett 2006;17:1392-8. [PMID: 17194584 DOI: 10.1016/j.bmcl.2006.11.080] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2006] [Revised: 11/20/2006] [Accepted: 11/30/2006] [Indexed: 12/01/2022]
29
Mikamo H, Tanaka K, Watanabe K. [Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation]. THE JAPANESE JOURNAL OF ANTIBIOTICS 2006;59:468-73. [PMID: 17334064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
30
Natarajan SR, Liu L, Levorse M, Thompson JE, O'Neill EA, O'Keefe SJ, Vora KA, Cvetovich R, Chung JY, Carballo-Jane E, Visco DM. p38 MAP kinase inhibitors. Part 5: Discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold. Bioorg Med Chem Lett 2006;16:5468-71. [PMID: 16945534 DOI: 10.1016/j.bmcl.2006.06.084] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2006] [Revised: 06/07/2006] [Accepted: 06/08/2006] [Indexed: 11/22/2022]
31
Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS. The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone. Neuropharmacology 2006;50:677-89. [PMID: 16430927 DOI: 10.1016/j.neuropharm.2005.11.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2005] [Revised: 11/25/2005] [Accepted: 11/25/2005] [Indexed: 11/30/2022]
32
Buurman ET, Johnson KD, Kelly RK, MacCormack K. Different modes of action of naphthyridones in gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2006;50:385-7. [PMID: 16377719 PMCID: PMC1346805 DOI: 10.1128/aac.50.1.385-387.2006] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
33
Padeĭskaia EN. [Fluoroquinolones and therapy of bacterial meningitis]. ANTIBIOTIKI I KHIMIOTERAPIIA = ANTIBIOTICS AND CHEMOTERAPY [SIC] 2006;51:53-64. [PMID: 17165260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
34
Fukuda Y, Takahata M, Mitsuyama J. Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration. J Infect Chemother 2006;12:1-8. [PMID: 16506083 DOI: 10.1007/s10156-005-0420-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2005] [Accepted: 11/24/2005] [Indexed: 11/27/2022]
35
Ramanathan S, Karupiah S, Nair NK, Olliaro PL, Navaratnam V, Wernsdorfer WH, Mansor SM. A new and simple solid-phase extraction method for LC determination of pyronaridine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005;824:45-50. [PMID: 16046285 DOI: 10.1016/j.jchromb.2005.06.034] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2004] [Revised: 06/14/2005] [Accepted: 06/24/2005] [Indexed: 11/19/2022]
36
Embrey MW, Wai JS, Funk TW, Homnick CF, Perlow DS, Young SD, Vacca JP, Hazuda DJ, Felock PJ, Stillmock KA, Witmer MV, Moyer G, Schleif WA, Gabryelski LJ, Jin L, Chen IW, Ellis JD, Wong BK, Lin JH, Leonard YM, Tsou NN, Zhuang L. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett 2005;15:4550-4. [PMID: 16102965 DOI: 10.1016/j.bmcl.2005.06.105] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2005] [Revised: 06/30/2005] [Accepted: 06/30/2005] [Indexed: 10/25/2022]
37
Saravolatz L, Manzor O, Pawlak J, Belian B. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. Int J Antimicrob Agents 2005;26:81-4. [PMID: 15951159 DOI: 10.1016/j.ijantimicag.2005.03.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2004] [Accepted: 03/10/2005] [Indexed: 11/18/2022]
38
Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005;25:717-40. [PMID: 15899734 DOI: 10.1592/phco.25.5.717.63583] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
39
Azoulay-Dupuis E, Bédos JP, Mohler J, Moine P, Cherbuliez C, Peytavin G, Fantin B, Köhler T. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob Agents Chemother 2005;49:1046-54. [PMID: 15728901 PMCID: PMC549237 DOI: 10.1128/aac.49.3.1046-1054.2005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
40
Owens RC, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2005;51:45-9. [PMID: 15629228 DOI: 10.1016/j.diagmicrobio.2004.08.019] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2004] [Accepted: 08/30/2004] [Indexed: 10/26/2022]
41
Islinger F, Bouw R, Stahl M, Lackner E, Zeleny P, Brunner M, Müller M, Eichler HG, Joukhadar C. Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose. Antimicrob Agents Chemother 2004;48:4246-9. [PMID: 15504848 PMCID: PMC525435 DOI: 10.1128/aac.48.11.4246-4249.2004] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2004] [Revised: 05/24/2004] [Accepted: 07/20/2004] [Indexed: 11/20/2022]  Open
42
Coleman PJ, Brashear KM, Askew BC, Hutchinson JH, McVean CA, Duong LT, Feuston BP, Fernandez-Metzler C, Gentile MA, Hartman GD, Kimmel DB, Leu CT, Lipfert L, Merkle K, Pennypacker B, Prueksaritanont T, Rodan GA, Wesolowski GA, Rodan SB, Duggan ME. Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis. J Med Chem 2004;47:4829-37. [PMID: 15369386 DOI: 10.1021/jm049874c] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
43
Babalola CP, Scriba GKE, Sowunmi A, Alawode OA. Liquid chromatographic determination of pyronaridine in human plasma and oral dosage form. J Chromatogr B Analyt Technol Biomed Life Sci 2004;795:265-72. [PMID: 14522031 DOI: 10.1016/s1570-0232(03)00591-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
44
Yoo BK, Triller DM, Yong CS, Lodise TP. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections. Ann Pharmacother 2004;38:1226-35. [PMID: 15187209 DOI: 10.1345/aph.1e003] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
45
Malerczyk C, Kolbert M, Kinzig-Schippers M, Sörgel F, Machka K, Shah PM. Serum bactericidal activity of gemifloxacin versus clarithromycin against Streptococcus pneumoniae with different susceptibility to quinolones. J Chemother 2004;16:56-61. [PMID: 15078000 DOI: 10.1179/joc.2004.16.1.56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
46
Mise M, Yadera S, Matsuda M, Hashizume T, Matsumoto S, Terauchi Y, Fujii T. POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS. Drug Metab Dispos 2004;32:240-5. [PMID: 14744947 DOI: 10.1124/dmd.32.2.240] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]  Open
47
Firsov AA, Zinner SH, Lubenko IY, Portnoy YA, Vostrov SN. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy 2004;48:275-9. [PMID: 12673102 DOI: 10.1159/000069709] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
48
Barequet IS, Denton P, Osterhout GJ, Tuli S, O'Brien TP. Treatment of Experimental Bacterial Keratitis With Topical Trovafloxacin. ACTA ACUST UNITED AC 2004;122:65-9. [PMID: 14718297 DOI: 10.1001/archopht.122.1.65] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
49
Prueksaritanont T, Fernandez-Metzler C, Meng Y, Barrish A, Halczenko W, Rodan SB, Hutchinson JH, Duggan ME, Lin JH. Disposition of a novel and potent alpha(v)beta3 antagonist in animals, and extrapolation to man. Xenobiotica 2004;34:103-15. [PMID: 14742139 DOI: 10.1080/713767592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
50
Garrison MW, Schimmels JA, Madaras-Kelly KJ. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV. Diagn Microbiol Infect Dis 2003;47:587-93. [PMID: 14711480 DOI: 10.1016/s0732-8893(03)00152-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
PrevPage 2 of 9 1234589Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA